Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

New single pill regimen simplifies treatment for resistant HIV

25

Feb 2026

New single pill regimen simplifies treatment for resistant HIV

A phase 3 clinical trial, led by Professor Chloe Orkin of Queen Mary University of London, has shown that a new, daily oral tablet that combines two current HIV treatment medications – bictegravir and lenacapavir (BIC/LEN) – may simplify treatment significantly for people with HIV who currently take very complex treatments.

Morning chronotype and exercise associated with reduced ALS risk

25

Feb 2026

Morning chronotype and exercise associated with reduced ALS risk

Being an early bird, also called a morning person, and being more physically active are associated with lower risks of amyotrophic lateral sclerosis (ALS), according to a preliminary study released February 25, 2026, that will be presented at the American Academy of Neurology's 78th Annual Meeting taking place April 18-22, 2026, in Chicago and online.

Prior COVID infection increases kidney disease risk

25

Feb 2026

Prior COVID infection increases kidney disease risk

Approximately one in seven adults in the United States has kidney disease, where the organs responsible for filtering waste and excess water from the blood are damaged, according to the Centers for Disease Control and Prevention.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.